KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456

RAS Proteins and Their Regulators in Human Disease

Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943

Lentivirus-delivered stable gene silencing by RNAi in primary cells.

Stewart, S. A., Dykxhoorn, D. M., Palliser, D., Mizuno, H., Yu, E. Y., An, D., Sabatini, D., Chen, I. S. Y., Hahn, W., Sharp, P., et al. (2003) · RNA: A publication of the RNA Society · doi:10.1261/rna.2192803 · Cited by 1,619

BRAF mutation predicts sensitivity to MEK inhibition

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326

Targeting RAS–ERK signalling in cancer: promises and challenges

Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163

Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer

Jonkers, J., Meuwissen, R. L. J., van der Gulden, H. M. L., Peterse, H. L., van der Valk, M., & Berns, A. J. M. (2001) · Nature Genetics · doi:10.1038/ng747 · Cited by 1,044

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786

Regulation of RAF protein kinases in ERK signalling

Lavoie, H., & Therrien, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3979 · Cited by 702

Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway

Hu, X., Zhang, R., Yao, J., Mu, B., & Zhao, C. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12891 · Cited by 4

Structural And Computational Perspectives of Selectively Targeting Mutant Proteins

Coban, M., Fraga, S., & Caulfield, T. R. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200311114819 · Cited by 4

Pharmacological SOS1 inhibitor BI-3406 demonstrates in vivo anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumorsPreprint

Baltanás, F. C., Kramer‐Drauberg, M., García‐Navas, R., Patrucco, E., Petrini, E., Arnhof, H., Juan, A. O.-S., Rodríguez-Ramos, P., Borrajo, J., Calzada, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.18.613686 · Cited by 4

Engineered protein circuits for cancer therapyPreprint

Lu, A. C., Moeller, L., Moore, S., Ho, K., Tobin, V., Qiang, A., Zhang, E., Li, Z., Wang, M., Xia, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.16.647665 · Cited by 5

AN IN SILICO AND IN VITRO EVALUATION OF CYTOTOXICITY, APOPTOTIC ACTIVITY AND GENE EXPRESSION MODULATION OF SARSASAPOGENIN IN HUMAN COLORECTAL CANCER CELL LINE HT-29

AHAMED, T., RAMASAMY, K., & Ramya, S. (2024) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2024v16i4.50855 · Cited by 3

KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis

Seguin, L. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-94004-1_10 · Cited by 3

The Self‐Association of the KRAS4b Protein is Altered by Lipid‐Bilayer Composition and Electrostatics

Lee, K., Ikura, M., & Marshall, C. B. (2023) · Angewandte Chemie · doi:10.1002/ange.202218698 · Cited by 3

Biochemical and biophysical characterization of the RAS family small GTPase protein DiRAS3

SAITOH, T., Kim, H.-N., Narita, R., Ohtsuka, I., Mo, W., Lee, K., Enomoto, M., Gasmi-Seabrook, G. M. C., Marshall, C. B., & Ikura, M. (2023) · Protein Expression and Purification · doi:10.1016/j.pep.2023.106361 · Cited by 3

Double base mismatches mediated catalytic hairpin assembly for enzyme-free single-base mutation detection: integrating signal recognition and amplification in one

Wang, L., Bu, S., Xu, S., Huang, T., Yang, F. W., Tan, Q., Deng, M., Xie, W., Cai, B., & Chen, J. (2024) · Microchimica Acta · doi:10.1007/s00604-024-06366-5 · Cited by 5

Oncogenic mutant KRAS inhibition through oxidation at cysteine 118

Kramer‐Drauberg, M., Petrini, E., Mira, A., Patrucco, E., Scardaci, R., Savinelli, I., Wang, H., Qiao, K., Carrà, G., Nokin, M., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.13798 · Cited by 3

Mutant Allele Imbalance in Cancer

Bielski, C. M., & Taylor, B. S. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-051320-124252 · Cited by 3

K-Ras G-domain binding with signaling lipid phosphoinositides: PIP2 association, orientation, functionPreprint

Cao, S., Chung, S., Kim, S., Li, Z., Manor, D., & Buck, M. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/324210 · Cited by 3

ProtCID: A data resource for structural information on protein interactionsPreprint

Xu, Q., & Dunbrack, R. L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/579862 · Cited by 6

Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancerPreprint

Cheng, D. K., Oni, T. E., Park, Y., Thalappillil, J. S., Ting, H.-C., Alagesan, B., Prasad, N. V., Rivera, K. D., Pappin, D., Aelst, L. V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.14.295394 · Cited by 3

Comprehensive multi-omics analysis of tandem duplicator phenotypes in non-small cell lung cancer

Li, J., Pan, X., Bi, Y., Huang, J., Peng, J., Bai, C., Hou, J., & Yang, C. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1556840 · Cited by 2

Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches

Karki, R., Chen, R., & Pan, S. (2025) · Current Oncology · doi:10.3390/curroncol32110614 · Cited by 3

The current understanding of KRAS oligomerization on membranes

Lesgidou, N., Papadourakis, M., Mandal, N., Dehghani‐Ghahnaviyeh, S., Velez‐Vega, C., Duca, J. S., & Cournia, Z. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103190 · Cited by 2

Unlocking the Genetic Secrets of Pancreatic Cancer: KRAS Allelic Imbalances in Tumor Evolution

Liaki, V., Rosas-Pérez, B., & Guerra, C. E. (2025) · Cancers · doi:10.3390/cancers17071226 · Cited by 2

Probing RAS Function Using Monobody and NanoBiT Technologies

Whaby, M., Nair, R. S., & O’Bryan, J. P. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3822-4_15 · Cited by 2

The structural basis of the oncogenic mutant K-Ras4B homodimersPreprint

Kosoglu, K., Omur, M. E., Jang, H., Nussinov, R., Keskin, Ö., & Gürsoy, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.07.285783 · Cited by 2

Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growthPreprint

Tang, R., Shuldiner, E. G., Kelly, M. R., Murray, C. W., Hebert, J. D., Andrejka, L., Tsai, M. K., Hughes, N. W., Parker, M. I., Cai, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.08.451571 · Cited by 2

Unraveling disulfidptosis for prognostic modeling and personalized treatment strategies in lung adenocarcinoma

Xu, X., Zhang, B., Zhang, J., & Ma, H. (2024) · Future Science OA · doi:10.1080/20565623.2024.2432211 · Cited by 1

A nucleotide‐independent, pan‐ RAS ‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Kapp, J. N., Verdurmen, W. P. R., Schaefer, J. V., Kopra, K., Nagy‐Davidescu, G., Richard, É., Nokin, M., Erñst, P., Tamaskovic, R., Schwill, M., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70061 · Cited by 1

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

Ballesteros-González, I., Hernández-Navas, I., Brehey, O., Lechuga, C. G., Salmón, M., Scotece, M., Velasco-Vicente, R., Flores-Gómez, A. A., Cebriá, A., Simón-Carrasco, L., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00326-z · Cited by 1

Intrinsic resistance to RAS inhibitors is driven by dysregulation of KRAS degradation

Ivanišević, T., Ma, Y., Boxel, E. V., Magits, W., Lechat, B., Koçberber, Z., Willnow, P., Fendt, S., Velde, G. V., Sewduth, R. N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67109-5 · Cited by 2

Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling

Tintelnot, J., Metz, S., Trentmann, M., Oberle, A., von Wenserski, L., Schultheiß, C., Braig, F., Kriegs, M., Fehse, B., Riecken, K., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01559 · Cited by 1

Combined computational and solution scattering methods to study the dynamical properties of Ras

Guterres (2018) · Digital Repository Service (Northeastern University) · doi:10.17760/d20287341 · Cited by 1

Membrane Composition and Raf[CRD]-Membrane Attachment Are Driving Forces for K-Ras4B Dimer StabilityPreprint

Cournia, Z., Andreadelis, I., Kiriakidi, S., Lamprakis, C., Theodoropoulou, A., Doerr, S., Chatzigoulas, A., Manchester, J. I., Velez‐Vega, C., & Duca, J. S. (2021) · doi:10.33774/chemrxiv-2021-4pdzb · Cited by 1

MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppressionPreprint

Farnsworth, D., Inoue, Y., Johnson, F. D., de Rappard-Yuswack, G., Lu, D., Shi, R., Somwar, R., Ladanyi, M., Unni, A. M., & Lockwood, W. W. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.29.490009 · Cited by 1

A cancer-associated K-RAS mutant that preferentially binds GDP displays gain-of-function and atypical signalingPreprint

Qian, X., Pantsar, T., Papageorge1, A. G., Tripathi, B. K., Sánchez‐Solana, B., Durkin, M. E., Gao, Y., Esposito, D., Waybright, T. J., Stephen, A. G., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1521657/v1 · Cited by 1

Wild kras inhibit the migration and invasion of pancreatic cancer through Wnt /β-catenin pathwayPreprint

Hu, X., Zhao, C., Zhang, R., Yao, J., & Mu, B. (2022) · Research Square · doi:10.21203/rs.3.rs-1908047/v1 · Cited by 1

Transcriptional Dosage of Oncogenic KRAS Drives Lung Adenocarcinoma Cell States, Progression and MetastasisPreprint

Serresi, M., Çetin, A. O., Dramaretska, Y., Kertalli, S., Schmitt, M. J., Naumann, H., Zschummel, M., Asselin-Labat, M.-L., Maciel, L. F., Declercq, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.29.630643 · Cited by 1

Synergistic RAS-MAPK and AKT Activation in MYC-Driven Tumors via Adjacent PVT1 RearrangementsPreprint

Tiwari, A., Paithane, U., Friedlein, J., Tashiro, K., Saulnier, O., Barbosa, K., Trinh, Q. M., Hall, B., Saha, S., Soni, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.17.638454 · Cited by 1

A Common PD-Risk GBA1 Variant Disrupts LIMP2 Interaction, Impairs Glucocerebrosidase Function, and Drives Lysosomal and Mitochondrial DysfunctionPreprint

Davis, O. B., Kung, J. E., Davis, S. S., Ghosh, R., Andrews, S. V., Gould, N. S., Kluss, J. H., Thomsen, E. R., Agam, M. R., Coan, J. P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.28.672891 · Cited by 2

Targeting Cancer from a Structural Biology Perspective

Reid, D. F., & Mattos, C. (2019) · Springer eBooks · doi:10.1007/978-981-32-9816-3_12

Mapping the unique and shared functions of oncogenic KRAS and RIT1 with proteome and transcriptome profilingPreprint

Lo, A., Holmes, K., Mundt, F., Moorthi, S., Fung, I., Fereshetian, S., Watson, J., Carr, S. A., Mertins, P., & Berger, A. H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.10.030460

Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer

Xu, J., Wang, X., Jiang, H., Chen, Y., Wang, R., & Shu, Y. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001070

Ras and Ras Signaling as a Therapeutic Target in Cancer

Sliker, B. H., & Campbell, P. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00006-2

Allosterism and Drug Discovery

Bell, J. E., & Bell, J. K. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc299

Membrane Composition and Raf[CRD]-Membrane Attachment Are Driving Forces for K-Ras4B Dimer StabilityPreprint

Cournia, Z., Andreadelis, I., Kiriakidi, S., Lamprakis, C., Theodoropoulou, A., Doerr, S., Chatzigoulas, A., Manchester, J. I., Velez‐Vega, C., & Duca, J. S. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-4pdzb

Faculty Opinions recommendation of MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance.

El‐Deiry, W. S., & Borerro, L. H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735662150.793560370

The Ras Dimer StructurePreprint

Rudack, T., Teuber, C., Scherlo, M., Güldenhaupt, J., Schartner, J., Lübben, M., Klare, J. P., Gerwert, K. B., & Kötting, C. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14039810

Modeling and Simulation of Lipid Membranes

Marti, J., & Calero, C. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-4938-5

Evaluation of K-Ras4B dimer interfaces and the role of Raf effectorsPreprint

Chatzigoulas, A., Andreadelis, I., Doerr, S., Lamprakis, C., Theodoropoulou, A., Manchester, J. I., Velez‐Vega, C., Duca, J. S., & Cournia, Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.04.510804

Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patientsPreprint

Ren, Q., Li, Q., Shao, C., Zhang, P., Hu, Z., Li, J., Wang, W., & Yu, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2520613/v1

3DVizSNP: a tool for rapidly visualizing missense mutations identified in high throughput experiments in iCn3D

Sierk, M. L., Ratnayake, S., Wagle, M. M., Chen, B., Park, B., Wang, J., Youkharibache, P., & Meerzaman, D. M. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05370-5

KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivoPreprint

Najumudeen, A. K., Fey, S. K., Millett, L. M., Ford, C. A., Gilroy, K. L., Gündüz, N., Ridgway, R. A., Anderson, E., Strathdee, D., Clark, W. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.29.555396

Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivityPreprint

Fey, S. K., Najumudeen, A. K., Ford, C. A., Gilroy, K. L., Upstill‐Goddard, R., Chang, D. K.-F., Clark, W., Nixon, C., Barry, S. T., Morton, J. P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.29.552598

Conditional Cooperativity in RAS Assembly Pathways on Nanodiscs and Altered GTPase Cycling

Lee, S., & Lee, K. (2024) · Angewandte Chemie · doi:10.1002/ange.202316942

Additional file 1 of 3DVizSNP: a tool for rapidly visualizing missense mutations identified in high throughput experiments in iCn3D

Sierk, M. L., Ratnayake, S., Wagle, M. M., Chen, B., Park, B., Wang, J., Youkharibache, P., & Meerzaman, D. M. (2023) · Figshare · doi:10.6084/m9.figshare.23488967

Allosteric interactions in KRas and HRas: studies of KRas/Calmodulin and HRas/Raf-RBD

Ojeda, M. (2023) · Digital Repository Service (Northeastern University) · doi:10.17760/d20621550

Therapeutic Targeting of KRAS Oncogene in Pancreatic Ductal Adenocarcinoma (PDAC)

Song, J. J. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i1.6375

Discovery and development of Krazati (adagrasib/MRTX849), a potent, selective, orally bioavailable, covalent KRASG12C(OFF) inhibitor

Gill, A. L., & Marx, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00017-6

Pharmacologically active antibodies for treatment of cancer and pain

Jungholm, O. (2025) · doi:10.69622/28750253.v1

Elevated KRAS protein level is associated with better survival in pancreatic cancer

Stålberg, S. M., Silwal‐Pandit, L., Hamfjord, J., Nebdal, D. J. H., Lehtiö, J., Lingjærde, O. C., Skålhegg, B. S., & Kure, E. H. (2025) · BMC Cancer · doi:10.1186/s12885-025-14461-w · Cited by 1

Additional file 1 of Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients

Ren, Q., Li, Q., Shao, C., Zhang, P., Hu, Z., Li, J., Wang, W., & Yu, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24187825

Additional file 3 of Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients

Ren, Q., Li, Q., Shao, C., Zhang, P., Hu, Z., Li, J., Wang, W., & Yu, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24187831

Additional file 2 of Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients

Ren, Q., Li, Q., Shao, C., Zhang, P., Hu, Z., Li, J., Wang, W., & Yu, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24187828

Additional file 4 of Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients

Ren, Q., Li, Q., Shao, C., Zhang, P., Hu, Z., Li, J., Wang, W., & Yu, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24187834

Activation des petites GTPases à la périphérie des membranes

Peurois, F. (2018) · doi:10.70675/17a7d716zcb19z4e3cz9dbfz49690c621294

Control of antitumor immunity by the SQSTM1 dependent signaling

Yazbeck, N. (2018) · doi:10.70675/3eee578bzb29fz4a95z8a1az99fa6d5edb80

Thérapies ciblées dans le mélanome : mécanismes impliqués dans les effets paradoxaux, les résistances et évaluation de nouvelles combinaisons

Boespflug, A. M. (2018) · theses.fr (ABES) · doi:10.70675/ea169901ze918z47cez92cfzc3665e19606a

Notch activation upon DNA damage : molecular characterisation and therapeutic applications in lung adenocarcinoma

Bernardo, S. (2019) · theses.fr (ABES) · doi:10.70675/df87afcbz5843z4c32z9d7cz074065a8acf1

Hététogénéité intratumorale et dynamique des populations du carcinome hépatocellulaire : impact de l’intensité de la signalisation Ras/MAPK Erk

Lozano, A. (2021) · theses.fr (ABES) · doi:10.70675/a2b1195ez9acdz4848za284z48d03d642274

MAPK pathway modulation and its implications in KRAS mutant lung adenocarcinoma

Román, S. D. H. (2023) · theses.fr (ABES) · doi:10.70675/8eaccae1ze96bz4279zb69fzaafa5e50c341

Plasmodium falciparum derived extracellular vesicles reprogram host MAP Kinase signalling cascade to promote cytoadherencePreprint

Shukla, M. S., Akhouri, R. R., & Goel, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.12.724568

Mirror-image mRNA display uncovers isoform-selective D-peptide macrocycles targeting a cryptic KRAS pocketPreprint

Mitcheltree, M. J., Boo, N., Boyer, N. C., Brown, Z. Z., Chai, X., Duggal, R., Garrigou, M., Hayes, R. P., Johnston, J. M., Josien, H. B., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.20.726527

Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them

Mariano, M. P., Sgarilli, E., Mijnlieff, D., Visuvasam, B., Blesio, A., Digiacomo, G., Cavazzoni, A., Ferracin, M., & Giovannetti, E. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2026.52

Regulation of Membrane Association and Downstream Effector Interaction of K-Ras by Its Hypervariable Region

Trifan, A., Omidi-Ardali, H., Vermaas, J. V., Rudack, T., & Tajkhorshid, E. (2026) · Membranes · doi:10.3390/membranes16090304

FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non–small cell lung cancer

Coma, S., Musteanu, M., Malvezzi, C. C., Jamieson, R., Patrucco, E., Mira, A., Dilly, J., Li, Z., Fernández‐Rodríguez, A., López-García, A., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aea4608

BindingDB Entry 50017595: Efficient targeted oncogenic KRAS

BindingDB (2023) · UC San Diego · doi:10.7270/q2639ttm

Uncovering KRAS -mutant allele-specific biology and vulnerabilities in non-small cell lung cancer

d’Arienzo, P. D., McDaid, W. J., Tinsley, K. L., Chen, T., Gasson, E. J., Lindsay, C. R., & Malliri, A. (2026) · Biochemical Journal · doi:10.1042/bcj20250138

P3.02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma

Ambrogio, C., Köhler, J., Zhou, Z., Wang, H., Paranal, R. M., Capelletti, M., Caffarra, C., Li, S., Lv, Q., Gondi, S. R., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.1595 · Cited by 1

Wild-type KRAS mediates growth inhibition and resistance to MEK inhibitors through dimerization with mutant KRAS in lung adenocarcinoma

Ambrogio, C., Köhler, J., Zhou, Z., Wang, H., Paranal, R. M., Capelletti, M., Caffarra, C., Li, S., Lv, Q., Santamarı́a, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx361 · Cited by 3

IA02 Insights into KRAS Biology to Identify Potential Therapeutic Strategies

Ambrogio, C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.003 · Cited by 1

Abstract IA05: Dimerization is critical for the functions of wild-type and mutant KRAS

Ambrogio, C. (2020) · Molecular Cancer Research · doi:10.1158/1557-3125.ras18-ia05

Dimerization Is Critical for the Functions of Wild-type and Mutant KRAS

(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2018-013 · Cited by 1